Capecitabine Teva
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
Name | Capecitabine Teva |
---|---|
Active Substance | kapecitabin |
Prescription | na recept |
Type of prescription | ograničeni recept |
Distribution | u ljekarni |
ATC Code | L01BC06 |
Medicinal product marketed in the Croatia | Da |
Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
Link to the European Medicines Agency's (EMA) product information | download |
Link to the European Commission's (EC) decisions | download |
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o potrebi testiranja bolesnika prije započinjanja liječenja lijekovima s djelatnim tvarima fluorouracil, kapecitabin ili tegafur radi utvrđivanja mogućeg nedostatka DPD enzima koji bolesnike izlaže povećanom riziku od teške toksičnosti | 04.06.2020 | Roche Registration GmbH, Jadran Galenski laboratorij d.d. (JGL), Alpha-Medical d.o.o., Sandoz d.o.o., Alvogen Pharma Trading Europe EOOD, Pliva Hrvatska d.o.o., Krka-farma d.o.o., Teva B.V., Accord Healthcare S.L.U. |